ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2010
Stereotactic body radiotherapy for lung tumors at the pulmonary hilum.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014Guideline
- LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.The British journal of radiology · 2015Trial
- Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Trial
- [Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery : QUIRO-DEGRO Trial].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2012Trial
- Safety and Efficacy of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Cancer.Frontiers in oncology · 2022Article
- A single institutional experience with central lung stereotactic body radiation therapy demonstrating encouraging results with increased inter-fraction time.Journal of thoracic disease · 2021Article
- Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.Thoracic cancer · 2020Article
- Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer.Translational lung cancer research · 2019Review
- Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes.Translational lung cancer research · 2019Review
- Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in seven fractions: A retrospective study.Oncology letters · 2018Article
- Specific toxicity after stereotactic body radiation therapy to the central chest : A comprehensive review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2017Review
- Mortality following single-fraction stereotactic body radiation therapy for central pulmonary oligometastasis.Journal of radiosurgery and SBRT · 2017Article
- Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Review
- Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases.Radiation oncology (London, England) · 2016Article
- Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?Translational lung cancer research · 2015Article
- Review
- Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2015Article
- Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.International journal of radiation oncology, biology, physics · 2014Article
- SBRT in operable early stage lung cancer patients.Translational lung cancer research · 2014Review
- Stereotactic body radiation therapy for centrally-located lung tumors.Oncology letters · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeHigh-dose irradiation to the pulmonary hilar region is generally considered to be of high risk in causing bronchial injury. The aim of this retrospective study is to investigate the safety and efficacy of stereotactic body radiotherapy (SBRT) for patients with lung tumors in the pulmonary hilum. PATIENTS AND
methods21 patients who underwent SBRT for lung tumors within 2 cm from a major bronchus were retrospectively analyzed. The total biologically effective doses ranging from 50.7 to 157.5 Gy (median, 100 Gy) were given to the tumors by SBRT.
resultsThe overall survival rates at 1 and 2 years after SBRT were 90.0% and 62.2%, respectively. Nine patients were alive and 15 irradiated tumors were controlled during the follow-up period of 10-54 months (median, 20 months). Nine patients died of tumor progression and one patient each died of hemoptysis, infectious pneumonia, and epidural hemorrhage. Severe late toxicity (>or= grade 3) was seen in three patients of whom two had previously received repeated radiotherapy.
conclusionSBRT for lung tumors located in the pulmonary hilar region may be tolerable and acceptable, if multiple treatments to the same major bronchus are avoided, and irradiated volumes are carefully taken into consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.